Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study.

Trial Profile

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Dacarbazine; Fotemustine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2011 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
    • 24 May 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top